



OPEN ACCESS

EDITED AND REVIEWED BY
Mathangi Gopalakrishnan,
University of Maryland, Baltimore,
United States

*CORRESPONDENCE
Miguel Sandonís
✉ miguel.sandonis@vallhebron.cat

†These authors have contributed equally
to this work

RECEIVED 22 July 2026
REVISED 23 July 2026
ACCEPTED 27 July 2026
PUBLISHED 10 August 2026

CITATION
Sandonís M, Brik M, Ramirez C,
Castellote L, Creus A, Parramón G,
Suy A, Ramos-Quiroga JA,
Palma-Álvarez RF and Daigre C
(2026) Correction: Breast milk Δ^9 -
tetrahydrocannabinol in cannabis
users during the postpartum period:
correlation between breast milk,
maternal urine and saliva samples
during early lactation.
Front. Psychiatry 17:1945694.
doi: 10.3389/fpsy.2026.1945694

COPYRIGHT
© 2026 Sandonís, Brik, Ramirez,
Castellote, Creus, Parramón, Suy,
Ramos-Quiroga, Palma-Álvarez and
Daigre. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License](#)
(CC BY). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication
in this journal is cited, in accordance
with accepted academic practice. No
use, distribution or reproduction is
permitted which does not comply with
these terms.

Correction: Breast milk Δ^9 -tetrahydrocannabinol in cannabis users during the postpartum period: correlation between breast milk, maternal urine and saliva samples during early lactation

Miguel Sandonís^{1,2,3,4*}, Maia Brik^{5,6}, Clara Ramirez⁷,
Laura Castellote⁷, Anna Creus⁸, Gemma Parramón^{1,2,4},
Anna Suy⁵, Josep Antoni Ramos-Quiroga^{1,2,3,4},
Raul Felipe Palma-Álvarez^{1,2,3,4†} and Constanza Daigre^{1,2,3,4†}

¹Department of Mental Health, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²Psychiatry, Mental Health and Addictions Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Hospital Universitari Vall d'Hebron (IIS IR-HUVH), Barcelona, Catalonia, Spain, ³Biomedical Research Networking Center in Mental Health (CIBERSAM), Barcelona, Spain, ⁴Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain, ⁵Department of Obstetrics and Gynecology, Universitat Autònoma de Barcelona, Barcelona, Spain, ⁶Obstetrics Department, Maternal-Fetal Medicine Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ⁷Clinical Biochemistry Research Group, Vall d'Hebron Research Institute (VHIR), Biochemical Core Facilities, Instituto de Investigación Sanitaria Hospital Universitari Vall d'Hebron (IIS IR-HUVH), Barcelona, Catalonia, Spain, ⁸Department of Neonatology, Hospital Universitari Vall d'Hebron, Barcelona, Spain

KEYWORDS

cannabis, pregnancy, breastfeeding, postpartum, perinatal

A Correction on

Breast milk Δ^9 -tetrahydrocannabinol in cannabis users during the postpartum period: correlation between breast milk, maternal urine and saliva samples during early lactation

By Sandonís M, Brik M, Ramirez C, Castellote L, Creus A, Parramón G, Suy A, Ramos-Quiroga JA, Palma-Álvarez RF and Daigre C (2026) *Front. Psychiatry* 17:1816611. doi: 10.3389/fpsy.2026.1816611

In the published article, in Section 3, Results, page 5, [Table 1](#), the neonatal urine toxicology data were reported incorrectly.

The published table included only the row “THC in newborn urine: Negative, n (%)”, and the values shown in that row were incorrect. The table should include both neonatal urine toxicology categories, positive and negative.

The corrected values are shown in the table below. Specifically, 6/13 newborns had a positive urine THC result and 7/13 newborns had a negative urine THC result. This correction affects only the descriptive neonatal toxicology data presented in [Table 1](#) and does not affect the study results, interpretation, or conclusions.

The corrected [Table 1](#) is below.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 Baseline sociodemographic and clinical characteristics.

Variable	Remained abstinent after delivery (n=11)	Reported cannabis use after delivery (n=2)	Total sample (n=13)
Maternal sociodemographic and clinical characteristics			
Age (years), mean $\pm$ SD	28.00 $\pm$ 6.77	30.00 $\pm$ 2.83	28.31 $\pm$ 6.28
Height (cm), mean $\pm$ SD	161.91 $\pm$ 6.55	159.50 $\pm$ 7.78	161.54 $\pm$ 6.45
Weight (kg), mean $\pm$ SD	66.88 $\pm$ 14.57	43.75 $\pm$ 8.84	63.32 $\pm$ 16.09
Body mass index, mean $\pm$ SD	25.52 $\pm$ 5.55	17.00 $\pm$ 1.98	24.21 $\pm$ 6.02
Nationality: Spanish, n (%)	9 (81.8%)	2 (100.0%)	11 (84.6%)
Nationality: Other, n (%)	2 (18.2%)	0 (0.0%)	2 (15.4%)
Civil status: Single, n (%)	2 (18.2%)	1 (50.0%)	3 (23.1%)
Civil status: Married/partner, n (%)	9 (81.8%)	1 (50.0%)	10 (76.9%)
Education duration <6 years, n (%)	6 (54.5%)	2 (100.0%)	8 (61.5%)
Education duration >6 years, n (%)	5 (45.5%)	0 (0.0%)	5 (38.5%)
Employment status: Employed, n (%)	3 (27.3%)	1 (50.0%)	4 (30.8%)
Employment status: Unemployed, n (%)	8 (72.7%)	1 (50.0%)	9 (69.2%)
Relevant medical history: Yes, n (%)	2 (18.2%)	1 (50.0%)	3 (23.1%)
Relevant medical history: No, n (%)	9 (81.8%)	1 (50.0%)	10 (76.9%)
Pregnancy, delivery, and neonatal outcomes			
Gestational age at delivery (weeks), mean $\pm$ SD	38.33 $\pm$ 1.51	34.20 $\pm$ 0.28	37.70 $\pm$ 2.08
Type of delivery: Vaginal delivery, n (%)	6 (54.5%)	0 (0.0%)	6 (46.2%)
Type of delivery: Assisted vaginal delivery, n (%)	1 (9.1%)	0 (0.0%)	1 (7.7%)
Type of delivery: Cesarean section, n (%)	4 (36.4%)	2 (100.0%)	6 (46.2%)
THC in newborn urine: Positive, n (%)	6 (54.5%)	0 (0.0%)	6 (46.2%)
THC in newborn urine: Negative, n (%)	5 (45.5%)	2 (100.0%)	7 (53.8%)
Birth weight (g), mean $\pm$ SD	2745.0 $\pm$ 409.41	2030.0 $\pm$ 70.71	2635.0 $\pm$ 460.65
Birth weight percentile, mean $\pm$ SD	21.27 $\pm$ 16.19	29.50 $\pm$ 2.12	22.54 $\pm$ 15.11
Newborn length at birth (cm), mean $\pm$ SD	48.19 $\pm$ 1.83	42.0 $\pm$ 1.41	47.23 $\pm$ 2.89
Birth length percentile, mean $\pm$ SD	31.36 $\pm$ 25.50	13.50 $\pm$ 14.85	28.62 $\pm$ 24.60
Head circumference (cm), mean $\pm$ SD	33.64 $\pm$ 1.80	30.50 $\pm$ 0.71	33.15 $\pm$ 2.04
Head circumference percentile, mean $\pm$ SD	33.82 $\pm$ 26.27	24.0 $\pm$ 7.07	32.31 $\pm$ 25.35
Apgar score at 1 min, mean $\pm$ SD	8.09 $\pm$ 2.55	6.50 $\pm$ 0.71	7.85 $\pm$ 2.41
Psychiatric and substance use history			
Family history of psychiatric disorders: Yes, n (%)	1 (9.1%)	2 (100.0%)	3 (23.1%)
Family history of psychiatric disorders: No, n (%)	10 (90.9%)	0 (0.0%)	10 (76.9%)
Personal history of psychiatric disorders: Yes, n (%)	5 (45.5%)	1 (50.0%)	6 (46.2%)
Personal history of psychiatric disorders: No, n (%)	6 (54.5%)	1 (50.0%)	7 (53.8%)
Tobacco use disorder: Yes, n (%)	6 (54.5%)	2 (100.0%)	8 (61.5%)
Tobacco use disorder: No, n (%)	5 (45.5%)	0 (0.0%)	5 (38.5%)

(Continued)

TABLE 1 Continued

Variable	Remained abstinent after delivery (n=11)	Reported cannabis use after delivery (n=2)	Total sample (n=13)
Psychiatric and substance use history			
Cannabis use onset (years), mean ± SD	15.45 ± 2.11	16.00 ± 0.00	15.54 ± 1.94
Cannabis use before pregnancy (joints/day), mean ± SD	6.27 ± 6.34	15.5 ± 20.51	7.69 ± 8.98
Cannabis use during pregnancy (joints/day), mean ± SD	1.45 ± 0.93	1.0 ± 0.0	1.39 ± 0.87

Data are presented as mean ± standard deviation or n (%).
BMI, body mass index; SD, standard deviation; THC, tetrahydrocannabinol.
Education duration refers to total years of formal education. Relevant medical history refers to chronic or clinically relevant medical conditions recorded in the maternal clinical history.
Birth weight and birth length percentiles were calculated using World Health Organization (WHO) growth references and were adjusted for gestational age and sex.